CSPC Pharmaceutical Group (HKG:1093) started a Phase Ib/II clinical trial in China of its experimental drug SYH2051 in combination with irinotecan liposome for the treatment of advanced solid tumors.
The multicenter, open-label trial will assess the safety and efficacy of the combination in patients with advanced solid tumors, according to a Monday Hong Kong bourse filing. Recruitment and screening are underway.